Newsroom Archives - Page 15 of 24 - Spectral Medical Inc

US FDA Grants Spectral Medical Breakthrough Device Designation for Toraymyxin™ (“PMX”) for the Treatment of Endotoxemic Septic Shock

Breakthrough designation expected to help accelerate regulatory review TORONTO, Canada – July 11, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today...

Spectral Medical Inc. Announces Results of Annual and Special Meeting of Shareholders

TORONTO, June 21, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting...

Spectral and Dialco Announce Dr. John Kellum to be Featured as Keynote Lecturer at the 40th Vicenza Course on AKI and CRRT 2022

Dr. Kellum Invited to Participate on Additional Featured Panels TORONTO, Canada – June 14, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT) a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as...

Spectral Medical Announces Adoption of SAMI Device by the Largest Inpatient Dialysis Provider in South Florida

TORONTO, Canada – June 13, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal...

Spectral Medical Announces Appointment of Leading Industry Executive Sam Amory as Dialco President

Previously launched start-up division for a major medical device company that grew to the number two position in the U.S. market TORONTO, Canada –May 16, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing...

Spectral to Present at Microcap Rodeo’s Spring into Action Best Ideas Virtual Conference on May 16th

TORONTO, Canada –May 13, 2022 – Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late stage theranostic company advancing therapeutic options for sepsis and septic shock, as well as commercializing a new proprietary platform targeting the renal...

« Older Entries

Next Entries »

EAA™ and PMX are licensed and available for use in Canada. PMX is not approved for clinical use in the USA, and is currently undergoing the PMA (Premarket approval) process. EAA™ is FDA cleared for use in the USA. The information presented herein is region specific. Please contact Spectral Medical Inc.to obtain appropriate product information for your country.